New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
06:10 EDTACHNAchillion begins dosing with ACH-3422 in its ongoing Phase 1 clinical trial
Achillion Pharmaceuticals announced the Company has begun dosing ACH-3422, a uridine-analog nucleotide polymerase inhibitor, for seven days in patients with genotype 1 chronic hepatitis C viral infection, or HCV, in its ongoing Phase 1 clinical trial. Proof-of-concept results from this trial are expected to be reported during the fall of 2014. Furthermore, Achillion announced that the FDA has removed the clinical hold on sovaprevir, an NS3/4A protease inhibitor, to permit the conduct of trials in patients with HCV.
News For ACHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
10:01 EDTACHNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:35 EDTACHNAchillion initiated with an Underweight at Barclays
Barclays started shares of Achillion with an Underweight rating and $8 price target citing the company's lateness to the hepatitis C market as well as competition in the space.
February 24, 2015
10:34 EDTACHNAchillion March calls active on renewed takeover chatter
Achillion March 14 and April 15 calls are active on total call volume of 1,600 contracts (100 puts) on renewed takeover chatter. February weekly call option implied volatility is at 82, March and April is at 79, June is at 81; compared to its 10-week average of 81 according to Track Data. Active call volume suggests traders taking positions for large near term price movement.
10:22 EDTACHNRumor: Achillion moves positive on renewed takeover chatter
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use